NCT01833039 2025-02-03
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Janssen Biotech, Inc.
Approved for marketing
Clinical Trials
10 trialsNCT05172700 2024-12-18
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
Eli Lilly and Company
Approved for marketing
NCT03153462 2023-11-08
ZUMA-9
Gilead Sciences
Approved for marketing
NCT05733650 2023-05-25
Expanded Access Program for Epcoritamab
Genmab
Approved for marketing
NCT04162756 2021-10-14
ZUMA-18
Gilead Sciences
Approved for marketing
NCT04943952 2021-08-03
JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase
Jazz Pharmaceuticals
Approved for marketing
NCT04300803 2020-08-28
Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL
MorphoSys AG
Approved for marketing
NCT02437019 2017-03-20
Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Janssen-Cilag Farmaceutica Ltda.
Approved for marketing
NCT02136511 2014-10-28
Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia
Gilead Sciences
Approved for marketing
NCT00481559 2014-01-17
Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity
BTG International Inc.
Approved for marketing